On November 7th, during the 7th CIIE, Abbott announced the launch of its new women's health drug Fenyuening in China. This medication is suitable for treating estrogen deficiency symptoms in women who have been postmenopausal for at least 12 months. It is reported that this drug is the first continuous combination preparation in China containing estrogen and progesterone components selected by authoritative guidelines.